Trial Profile

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB MRNA Degrader, in Patients with Relapsed/Refractory AML or Higher-Risk MDS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REM 422 (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions
Sponsors Remix Therapeutics

Most Recent Events

02 May 2024 According to Remix Therapeutics media release, the first patient enrolled and dosed in this Phase 1 clinical trial
29 Apr 2024 Status changed from not yet recruiting to recruiting.
03 Apr 2024 Planned initiation date changed from 15 Mar 2024 to 15 Apr 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com